Cytokeratin expression in malignant melanoma: Potential application of in-situ hybridization analysis of mRNA

Melanoma Research

Volumn 19, Issue 2, 2009, Pages 87-93

  Chen, Ni ^a,b   Gong, Jing ^a,b   Chen, Xueqin ^a,b   Xu, Miao ^a,b   Huang, Ying ^a,b   Wang, Lin ^c   Geng, Ning ^a   Zhou, Qiao ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b Department of Pathology ^*

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; CYTOKERATIN 10; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 6; CYTOKERATIN 7; CYTOKERATIN 8; CYTOKERATIN 9; CYTOKERATIN AE1; CYTOKERATIN AE3; MESSENGER RNA; KERATIN; RNA; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MELANOMA; METASTASIS; MUCOSA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; WESTERN BLOTTING; BIOSYNTHESIS; BONE TUMOR; BRAIN TUMOR; CHEMISTRY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR; TUMOR CELL LINE;

BLOTTING, WESTERN; BONE NEOPLASMS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; KAPLAN-MEIERS ESTIMATE; KERATIN-18; KERATINS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SKIN NEOPLASMS;

EID: 65449137964     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283252feb     Document Type: Article

References (22)

1. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40:403-439.
2. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31:11-24.
3. Shoup SA, Johnston WW, Siegler HF, Tello JW, Schlom J, Bigner DD, et al. A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma. Acta Cytol 1990; 34:385-392.
4. Listrom MB, Dalton LW. Comparison of keratin monoclonal antibodies MAK-6, AE1:AE3, and CAM-5.2. Am J Clin Pathol 1987; 88:297-301.
5. Leader M, Patel J, Makin C, Henry K. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology 1986; 10:1315-1324.
6. Korabiowska M, Fischer G, Steinacker A, Stachura J, Cordon-Cardo C, Brinck U. Cytokeratin positivity in paraffin-embedded malignant melanomas: comparative study of KL1, A4 and Lu5 antibodies. Anticancer Res 2004; 24 :3203-3207.
7. Ben-Izhak O, Stark P, Levy R, Bergman R, Lichtig C. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases. Am J Dermatopathol 1994; 16:241-246.
8. Zarbo RJ, Gown AM, Nagle RB, Visscher DW, Crissman JD. Anomalous cytokeratin expression in malignant melanoma: one- and two-dimensional western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol 1990; 3:494-501.
9. Gatter KC, Ralfkiaer E, Skinner J, Brown D, Heryet A, Pulford KA, et al. An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours. J Clin Pathol 1985; 38 :1353-1357.
10. Achilles E, Schroder S. Positive cytokeratin results in malignant melanoma. Pitfall in differential immunohistologic diagnosis of occult neoplasms. Pathologe 1994; 15:235-241.
11. Katagata Y, Kondo S. Keratin expression and its significance in five cultured melanoma cell lines derived from primary, recurrent and metastasized melanomas. FEBS Lett 1997; 407:25-31.
12. Katagata Y, Aoki T, Hozumi Y, Yoshida T, Kondo S. Identification of K1/K10 and K5/K14 keratin pairs in human melanoma cell lines. J Dermatol Sci 1996; 13:219-227.
13. Trejdosiewicz LK, Southgate J, Kemshead JT, Hodges GM. Phenotypic analysis of cultured melanoma cells. Expression of cytokeratin-type intermediate filaments by the M5 human melanoma cell line. Exp Cell Res 1986; 164:388-398.
14. Fetsch PA, Marincola FM, Abati A. Cytokeratin positivity in fine-needle aspirates of metastatic malignant melanoma: fact or fiction? Diagn Cytopathol 1999; 20:249-252.
15. Plaza JA SD, Perez-Montiel D. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol 2007; 15:421-425.
16. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
17. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56:828-834.
18. Prasad ML, Patel S, Hoshaw-Woodard S, Escrig M, Shah JP, Huvos AG, et al. Prognostic factors for malignant melanoma of the squamous mucosa of the head and neck. Am J Surg Pathol 2002; 26:883-892.
19. Miettinen M, Franssila K. Immunohistochemical spectrum of malignant melanoma. The common presence of keratins. Lab Invest 1989; 61:623-628.
20. Bishop PW, Menasce LP, Yates AJ, Win NA, Banerjee SS. An immunophenotypic survey of malignant melanomas. Histopathology 1993; 23 :159-166.
21. Korabiowska M, Ruschenburg I, Schulz H, Steinacker A, Bortkiewicz P, Sevenich M, et al. Cytokeratin expression correlates with aneuploidy in cytological specimens of melanoma metastases. Anticancer Res 2005; 25 :2789-2792.
22. Fuchs U, Kivela T, Summanen P, Immonen I, Tarkkanen A. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol 1992; 141:169-181.